Establishment and popularization of intelligent diagnosis and follow-up system for hereditary deafness

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036832

Enrollment

Unknown

Registered

2020-08-25

Start date

2020-10-01

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hereditary deafness

Interventions

Gold Standard:Sanger sequencing

Index test:Pure-tone audiometry(PTA),Auditory brainstem response(ABR),whole-exomesequencing(WES)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) All patients were Chinese population, and all of them were bilateral congenital deafness; (2) The patients were diagnosed as sensorineural hearing loss, and the hearing loss was more than moderate and severe; (3) Patients may have a history of aminoglycoside use before deafness; (4) In the case of familial disease, only one of them was included in the study.

Exclusion criteria

Exclusion criteria: (1) Hearing loss was caused by malformation of the outer or middle ear; (2) Hearing loss was caused by brain injury; (3) Deafness or hearing loss caused by otitis media; (4) There was a history of middle ear surgery; (5) There was a history of high noise exposure; (6) Hearing loss was caused by high fever; (7) There were central diseases or other mental disorders.

Design outcomes

Primary

Measure	Time frame
gene;hearing;	—

Countries

China

Contacts

Public ContactYilai Shu

Eye & ENT Hospital of Fudan University

yialishu@163.com+86 21 64377134 2935

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026